Coenzyme Q10 Migraine Randomized Trial: What the Evidence Says

Quick Answer

Coenzyme Q10 Migraine Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• In addition to its high prevalence and disability burden, migraine is associated with substantial socioeconomic costs, with estimated direct and indirect expenditures of approximately USD 36 billion annually in the United States. [Kozák Márk (2026); evidence level 3]
• Clinically, migraine is characterized by recurrent attacks of moderate-to-severe headache lasting 4-72 h, typically unilateral and pulsating, aggravated by routine physical activity, and frequently accompanied by photophobia and phonophobia; in a substantial subset of patients, attacks are associated with reversible focal neurological symptoms called aura. [Kozák Márk (2026); evidence level 3]
• Migraine is a chronic, disabling neurovascular disorder characterized by recurrent episodes of moderate-to-severe headache, typically unilateral and pulsating in quality, and frequently associated with nausea, vomiting, photophobia, and phonophobia. [Santangelo Domenico (2026); evidence level 3]
• These processes result in peripheral and central sensitization of nociceptive pathways, thereby amplifying pain perception and contributing to migraine chronicization. [Santangelo Domenico (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For coenzyme q10 migraine randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Kozák Márk (2026). Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics. DOI: 10.3390/nu18050720. PMCID: PMC12986976. PMID: 41829891. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12986976/
• Santangelo Domenico (2026). Dietary Modulation of Migraine: Metabolic, Neuroinflammatory and Microbiota-Mediated Mechanisms. DOI: 10.3390/jcm15041476. PMCID: PMC12942355. PMID: 41753160. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12942355/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.